All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

CAPTIVATE 5.5-year update: Fixed-duration ibrutinib + venetoclax in patients with CLL/SLL and high-risk genomic features or progressive disease

Jul 1, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic lymphocytic leukemia/small lymphocytic lymphoma.

The phase II CAPTIVATE trial (NCT02910583) evaluated ibrutinib + venetoclax in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in two cohorts: measurable residual disease-guided cohort and fixed duration (FD) cohort. During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, 5.5-year follow-up outcomes of patients with high-risk genomic features from the FD cohort and retreatment outcomes in patients with progressive disease (PD) were presented by Wierda.1

Key learnings:

After 5.5 years of follow-up, median progression-free survival (PFS) was not reached with FD ibrutinib + venetoclax.

While the 5-year PFS and overall survival rates for patients with high-risk genomic features were lower than those without, these patients had a clinically meaningful survival benefit with FD ibrutinib + venetoclax.

Among patients with PD following FD ibrutinib + venetoclax, retreatment with single-agent ibrutinib or ibrutinib + venetoclax led to durable responses with no new safety signals.

These findings support the use of ibrutinib + venetoclax, an all-oral, once-daily, chemotherapy-free FD regimen, as a first-line treatment for patients with CLL/SLL and highlight the positive benefit–risk profile of ibrutinib-based retreatment in patients who relapse.

  1. Wierda WG, Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Abstract #7009. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 31 – Jun 4, 2024; Chicago, US.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox